Risorse
Consigli per la lettura
Marzo 2026
- CLOSURE-AF: Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation
- COBRRA: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
- Review: Atrial fibrillation
Suggerimenti precedenti
- Febbraio 2026
-
- Review: Secondary prevention after ischemic stroke
- Review: New drug therapies for hypertension
- TUXEDO-2: Ticagrelor vs prasugrel in patients with diabetes and multivessel coronary artery disease
- ADAPT AF-DES: Therapy for atrial fibrillation in patients with drug-eluting stents
- Meta-analysis: Assessment of adverse effects attributed to statin therapy in product labels
- Review: The inherited basis of coronary artery disease
- CORALreef Lipids: A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide
- Gennaio 2026
-
- Review: Heart failure with reduced ejection fraction
- TRICORDER: Triple cardiovascular disease detection with an AI-enabled stethoscope
- Review: Peripheral artery disease in the legs
- Review: Physiological pacing in heart failure
- Review: GLP-1 receptor agonists and incretin-based medications
- Review: Sudden cardiac arrest in athletes
- Debate: TAVR or SAVR for asymptomatic aortic stenosis
- Ability Diabetes Global: Abluminus DES SES vs EES in patients with diabetes and CAD
- Dicembre 2025
-
- Review: Heart failure with reduced ejection fraction
- TRICORDER: Triple cardiovascular disease detection with an AI-enabled stethoscope
- Review: Peripheral artery disease in the legs
- Review: Physiological pacing in heart failure
- Review: GLP-1 receptor agonists and incretin-based medications
- Review: Sudden cardiac arrest in athletes
- Debate: TAVR or SAVR for asymptomatic aortic stenosis
- Ability Diabetes Global: Abluminus DES SES vs EES in patients with diabetes and CAD
- Novembre 2025
-
- CREST-2: Terapia medica o rivascolarizzazione per la stenosi carotidea asintomatica
- Meta-analisi CRT: Rivascolarizzazione completa nell'infarto miocardico acuto
- Meta-analisi BBT: Beta-bloccanti dopo infarto con frazione d'eiezione normale
- OCEAN: Terapia antitrombotica dopo ablazione transcatetere
- VESALIUS-CV: Evolocumab in paziente senza precedente infarto o ictus
- ADAPT AF-DES: Terapia antitrombotica in pazienti con fibrillazione atriale trattati con DES
Linee guida cardiologiche europee (ESC)
- Aritmie sopraventricolari | 2019
- Aritmie ventricolari e morte cardiaca improvvisa | 2022
- Arteriopatie periferiche e aortopatie | 2024
- Cardiomiopatie | 2023
- Cardio-oncologia | 2022
- Cardiopatie congenite dell'adulto | 2020
- Definizione universale di infarto miocardico | 2018
- Diabete | 2023
- Dislipidemie | 2025 focused update
- Elettrostimolazione e resincronizzazione cardiaca | 2021
- Embolia polmonare acuta | 2019
- Endocarditi | 2023
- Fibrillazione atriale | 2024
- Gravidanza | 2025
- Ipertensione arteriosa | 2024
- Ipertensione polmonare | 2022
- Miocarditi e pericarditi | 2025
- Prevenzione cardiovascolare | 2021
- Rivascolarizzazione miocardica | 2018
- Salute mentale | 2025
- Scompenso cardiaco acuto e cronico | 2023 focused update
- Scompenso cardiaco | 2021
- Sincope | 2018
- Sindromi coronariche acute | 2023
- Sindromi coronariche croniche | 2024
- Sport | 2020
- Valvulopatie | 2025